Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches

Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) analysts were buying the stock. But one analyst has diluted ...